2017 Volume 37 Issue 5 Pages 723-727
Severe acute pancreatitis (SAP) is one of the diseases associated with disseminated intravascular coagulation (DIC). Recently, recombinant human soluble thrombomodulin (rTM) has been used as DIC therapy. We investigated the clinical outcomes in SAP patients with DIC at Showa University Hospital between January 2012 and December 2014. Approximately 50％ of SAP patients were complicated with DIC. More than 90％ of SAP patients with DIC were demonstrated organ dysfunctions, and approximately 40％ had walled-off necrosis. Improvement of DIC was suggested during the administration of rTM in SAP patients with DIC. Multi-center, randomized, controlled trials with larger numbers of patients are needed to evaluate the efficacy and safety of rTM in SAP patients with DIC.
